摘要
原癌基因的激活和抑癌基因的失活是肿瘤形成的重要分子机制.原癌基因HER-2是与乳腺癌的侵袭,转移及预后密切相关,HER-2过表达型乳腺癌进展快,预后差.近年来,针对HER-2结构构建具有靶向治疗作用的单克隆抗体药物曲妥珠单抗出现,显著提高了HER-2阳性晚期乳腺癌的疗效.
Oncogene activation and inactivation of tumor suppressor genes is an important molecular mechanism of tumor formation. HER-2 oncogene is associated with breast cancer invasion and metastasis and prognosis, HER-2 overexpressing breast cancer progresses rapidly and has poor prognosis. In recent years, the emergence of targeted therapeutic monoclonal antibody drug Herceptin which built its structure for the HER-2 has significantly inproved HER-2-positive advanced breast cancer.
出处
《昆明医科大学学报》
CAS
2013年第12期145-148,共4页
Journal of Kunming Medical University
基金
国家自然科学基金资助项目(81360069)
云南省自然科学基金资助项目(2010CD196)